Ankylosing Spondylitis
Conditions
Interventions
None listed
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Have AS according to the New York criteria - Be under the care of a rheumatologist - Start TNF inhibitors (adalimumab) as being part of current practice - BASDAI score of 4 or higher. - All subjects must be recruited within a period of 1 (one) year from the start of the longitudinal study.
Exclusion criteria
Exclusion criteria: - Have severe non-AS related co morbidity according to the diagnose treatment combination (DBC). Please note that this only applies for patients with a co-morbidity, by whom the treating doctor/rheumatologist decides they should not be included in the study because of health reasons. Patients who suffer from a co-morbidity without a non-immediate health risk will be included. Their situation will be assesses with the SQC questionnaire in order to correct for a confounding effect. - Have contra-indications (diagnosed by treating rheumatologist/specialist) for TNF inhibition - Do not understand the Dutch language - Do not have access to a computer with internet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A decrease in importance satisfaction gap of social participation areas over time in AS patients, due to a decrease of the disease burden, caused by treatment with anti-TNF-a (adalimumab) | — |
Secondary
| Measure | Time frame |
|---|---|
| (2) Understand which disease related and which contextual factors contribute to the change in restrictions of participation and in the gap between importance and satisfaction in participation areas. Several new variables will be assessed, such as: objectively assessed physical activity, body composition, beliefs/attitude regarding physical activity. (3) Changes in physical activity and body composition. Furthermore (4), the relation of participation and satisfaction with life is an important secondary parameter. | — |
Countries
Netherlands
Outcome results
None listed